Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT05756023
Recruiting Not applicable

IVF\ICSI Outcome in Women With Polycystic Ovary Syndrome

NCT05756023 · tracked via the Priya Life Science Egypt tracker
Sponsor
Egymedicalpedia
Phase
Not applicable
Started
2023-06-01
Last updated
2023-10-19

Condition(s) studied

PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

Investigational drug(s) / intervention(s)

the pregnancy rate at IVF / ICSI cycles

the pregnancy rate at IVF / ICSI cycles: To study and compare other parameters between the PCOS and non PCOS group, and inside the PCOS group itself eg ; patients with PCOS who have ovarian drilling and non drilling PCOS

Study summary

Polycystic ovarian syndrome (PCOS) occurs in 5% to 10% of all women of reproductive age and 50% of women who present with sub-fertility due to anovulatory infertility . Clear diagnostic criteria for this condition were identified at the consensus meeting of the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine .

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
35 Years
Healthy volunteers
No
Inclusion Criteria: * Oligo-ovulation or anovulation. * Clinical and/or biochemical hyper androgenesim. * Polycystic ovaries. Exclusion Criteria: 1. Androgen-secreting tumors (ovarian or adrenal). 2. Adult-onset congenital adrenal hyperplasia. 3. Thyroid diseases. 4. Cushing's syndrome. 5. Diabetes Mellitus. 6. recurrent ICSI failure 7. endocrine, hematologic and autoimmune disorders 8. Non chromosomal and genetic abnormalities 9. Major uterine anomalies, bad surgical history, sever endometriosis, , hydrosalpinx, uterine fibroids 10. Azospermia

Primary outcome measure(s)

  • pregnancy rate — From baseline to 15 days after the embryo transfere day.
    To compare the pregnancy rate at IVF / ICSI cycles between women with PCOS and non PCOS women

Trial sites (1)

FacilityCityRegionStatus
Assuit University hospitals Asyut Egypt Recruiting

Other trials for the same condition

Laboratory and Ultrasound Findings and Response to Letrozole in PCOS Patients Starting soon
Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05756023 on ClinicalTrials.gov ↗ ← All trials in Egypt